1932

Abstract

Hemophagocytic lymphohistiocytosis is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems. It is seen in both children and adults and is recognized as primary (driven by underlying genetic mutations that abolish critical proteins required for normal function of cytotoxic T cells and NK cells) or secondary (resulting from a malignant, infectious, or autoimmune stimulus without an identifiable underlying genetic trigger). Clinical and laboratory manifestations include fever, splenomegaly, neurologic dysfunction, coagulopathy, liver dysfunction, cytopenias, hypertriglyceridemia, hyperferritinemia, hemophagocytosis, and diminished NK cell activity. It is treated with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% of children who undergo transplant survive, but adults have quite poor outcomes even with aggressive management. Newer agents directed at subduing the uncontrolled immune response in a targeted fashion offer promise in this highly morbid disease.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pathol-020117-043625
2018-01-24
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/pathol/13/1/annurev-pathol-020117-043625.html?itemId=/content/journals/10.1146/annurev-pathol-020117-043625&mimeType=html&fmt=ahah

Literature Cited

  1. Chandrakasan S, Filipovich AH. 1.  2013. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J. Pediatr. 163:1253–59 [Google Scholar]
  2. Scott RB, Robb-Smith AHT. 2.  1939. Histiocytic medullary reticulosis. Lancet 2:194–98 [Google Scholar]
  3. Farquhar JW, Claireaux AE. 3.  1952. Familial haemophagocytic reticulosis. Arch. Dis. Child 27:519–25 [Google Scholar]
  4. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. 4.  2014. Adult haemophagocytic syndrome. Lancet 383:1503–16 [Google Scholar]
  5. Morimoto A, Nakazawa Y, Ishii E. 5.  2016. Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr. Int. 58:817–25 [Google Scholar]
  6. Ammann S, Lehmberg K, Zur Stadt U, Janka G, Rensing-Ehl A. 6.  et al. 2017. Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire. Eur. J. Immunol. 47:364–73 [Google Scholar]
  7. Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L. 7.  et al. 2007. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer 109:2566–71 [Google Scholar]
  8. Smith MC, Cohen DN, Greig B, Yenamandra A, Vnencak-Jones C. 8.  et al. 2014. The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder. Int. J. Clin. Exp. Pathol. 7:5738–49 [Google Scholar]
  9. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. 9.  2003. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 142:292–96 [Google Scholar]
  10. Asano T, Kogawa K, Morimoto A, Ishida Y, Suzuki N. 10.  et al. 2012. Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: a nationwide survey in Japan. Pediatr. Blood Cancer 59:110–14 [Google Scholar]
  11. Komp DM, McNamara J, Buckley P. 11.  1989. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 73:2128–32 [Google Scholar]
  12. Komp DM, Buckley PJ, McNamara J, van Hoff J. 12.  1989. Soluble interleukin-2 receptor in hemophagocytic histiocytoses: searching for markers of disease activity. Pediatr. Hematol. Oncol. 6:253–64 [Google Scholar]
  13. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. 13.  1991. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78:2918–22 [Google Scholar]
  14. Fujiwara F, Hibi S, Imashuku S. 14.  1993. Hypercytokinemia in hemophagocytic syndrome. Am. J. Pediatr. Hematol. Oncol. 15:92–98 [Google Scholar]
  15. Takada H, Nomura A, Ohga S, Hara T. 15.  2001. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk. Lymphoma 42:21–28 [Google Scholar]
  16. Tang Y, Xu X, Song H, Yang S, Shi S. 16.  et al. 2008. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br. J. Haematol. 143:84–91 [Google Scholar]
  17. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G. 17.  et al. 1997. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89:4100–3 [Google Scholar]
  18. Jordan MB, Hildeman D, Kappler J, Marrack P. 18.  2004. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104:735–43 [Google Scholar]
  19. Emile JF, Abla O, Fraitag S, Horne A, Haroche J. 19.  et al. 2016. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–81 [Google Scholar]
  20. Allen CE, McClain KL. 20.  2015. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematol. Am. Soc. Hematol. Educ. Program 2015:177–82 [Google Scholar]
  21. Feldmann J, Le Deist F, Ouachee-Chardin M, Certain S, Alexander S. 21.  et al. 2002. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br. J. Haematol. 117:965–72 [Google Scholar]
  22. Ueda I, Ishii E, Morimoto A, Ohga S, Sako M, Imashuku S. 22.  2006. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr. Blood Cancer 46:482–88 [Google Scholar]
  23. Niece JA, Rogers ZR, Ahmad N, Langevin AM, McClain KL. 23.  2010. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr. Blood Cancer 54:424–28 [Google Scholar]
  24. Schram AM, Berliner N. 24.  2015. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125:2908–14 [Google Scholar]
  25. Henter JI, Elinder G, Soder O, Ost A. 25.  1991. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr. Scand. 80:428–35 [Google Scholar]
  26. Riviere S, Galicier L, Coppo P, Marzac C, Aumont C. 26.  et al. 2014. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am. J. Med. 127:1118–25 [Google Scholar]
  27. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. 27.  2014. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin. Proc. 89:484–92 [Google Scholar]
  28. Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH. 28.  et al. 2011. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 118:4577–84 [Google Scholar]
  29. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A. 29.  et al. 2016. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br. J. Haematol. 172:412–19 [Google Scholar]
  30. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. 30.  2011. How I treat hemophagocytic lymphohistiocytosis. Blood 118:4041–52 [Google Scholar]
  31. Ravelli A, Davi S, Minoia F, Martini A, Cron RQ. 31.  2015. Macrophage activation syndrome. Hematol. Oncol. Clin. N. Am. 29:927–41 [Google Scholar]
  32. Zhang K, Chandrakasan S, Chapman H, Valencia CA, Husami A. 32.  et al. 2014. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 124:1331–34 [Google Scholar]
  33. Ohadi M, Lalloz MR, Sham P, Zhao J, Dearlove AM. 33.  et al. 1999. Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3–22 by homozygosity mapping. Am. J. Hum. Genet. 64:165–71 [Google Scholar]
  34. Goransdotter EK, Fadeel B, Nilsson-Ardnor S, Soderhall C, Samuelsson A. 34.  et al. 2001. Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am. J. Hum. Genet. 68:590–97 [Google Scholar]
  35. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D. 35.  et al. 2003. Munc13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461–73 [Google Scholar]
  36. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS. 36.  et al. 2005. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14:827–34 [Google Scholar]
  37. Cote M, Menager MM, Burgess A, Mahlaoui N, Picard C. 37.  et al. 2009. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J. Clin. Invest. 119:3765–73 [Google Scholar]
  38. Pagel J, Beutel K, Lehmberg K, Koch F, Maul-Pavicic A. 38.  et al. 2012. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 119:6016–24 [Google Scholar]
  39. Trizzino A, zur Stadt U, Ueda I, Risma K, Janka G. 39.  et al. 2008. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J. Med. Genet 4515–21 [Google Scholar]
  40. Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E. 40.  et al. 2011. Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J. Med. Genet 48343–52 [Google Scholar]
  41. Campo M, Berliner N. 41.  2015. Hemophagocytic lymphohistiocytosis in adults. Hematol. Oncol. Clin. N. Am. 29:915–25 [Google Scholar]
  42. Munoz J, Shareef N, Donthireddy V. 42.  2012. Cytomegalovirus-induced haemophagocytic lymphohistiocytosis syndrome. BMJ Case Rep https://doi.org/10.1136/bcr.10.2011.4963 [Crossref]
  43. Drori A, Ribak Y, van Heerden PV, Meir K, Wolf D, Safadi R. 43.  2015. Hemophagocytic lymphohistiocytosis due to acute primary herpes simplex virus 1 infection. J. Clin. Virol. 68:6–10 [Google Scholar]
  44. Ikumi K, Ando T, Katano H, Katsuno M, Sakai Y. 44.  et al. 2016. HSV-2-related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS. Neurol. Neuroimmunol. Neuroinflamm. 3:e247 [Google Scholar]
  45. van der Werff ten Bosch JE, Kollen WJ, Ball LM, Brinkman DM, Vossen AC. 45.  et al. 2009. Atypical varicella zoster infection associated with hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 53:226–28 [Google Scholar]
  46. Marabelle A, Bergeron C, Billaud G, Mekki Y, Girard S. 46.  2010. Hemophagocytic syndrome revealing primary HHV-6 infection. J. Pediatr. 157:511 [Google Scholar]
  47. Salle V, Desblache J, Mahevas M, Smail A, Schmidt J. 47.  et al. 2014. Syndrome hémophagocytaire associé à une infection HHV-8 d'évolution fatale chez une patiente non infectée par le VIH. [Fatal HHV-8-associated hemophagocytic syndrome in an HIV-negative patient]. Med. Mal. Infect 44437–40 [Google Scholar]
  48. Chung SM, Song JY, Kim W, Choi MJ, Jeon JH. 48.  et al. 2017. Dengue-associated hemophagocyticlymphohistiocytosis in an adult: a case report and literature review. Medicine (Baltimore) 96:e6159 [Google Scholar]
  49. van der Ven AJ, Netea MG, van der Meer JW, de Mast Q. 49.  2015. Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome. Front. Med. (Lausanne) 24 [Google Scholar]
  50. Tasdelen FN, Fisgin T, Tanyel E, Doganci L, Tulek N. 50.  et al. 2008. Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome. Am. J. Hematol. 83:73–76 [Google Scholar]
  51. Cron RQ, Behrens EM, Shakoory B, Ramanan AV, Chatham WW. 51.  2015. Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?. J. Rheumatol. 42:1078–80 [Google Scholar]
  52. Jin Y, Huang L, Fan H, Lu G, Xu Y, Wu Z. 52.  2016. Scrub typhus associated with hemophagocytic lymphohistiocytosis: a report of six pediatric patients. Exp. Ther. Med. 12:2729–34 [Google Scholar]
  53. Hui YM, Pillinger T, Luqmani A, Cooper N. 53.  2015. Haemophagocytic lymphohistiocytosis associated with Mycobacterium tuberculosis infection. BMJ Case Rep https://doi.org/10.1136/bcr-2014-208220 [Crossref]
  54. Kaplan RM, Swat SA, Singer BD. 54.  2016. Human monocytic ehrlichiosis complicated by hemophagocytic lymphohistiocytosis and multi-organ dysfunction syndrome. Diagn. Microbiol. Infect. Dis. 86:327–28 [Google Scholar]
  55. Mohyuddin GR, Male HJ. 55.  2016. A rare cause of hemophagocytic lymphohistiocytosis: Fusobacterium infection—a case report and review of the literature. Case Rep. Hematol. 2016:4839146 [Google Scholar]
  56. Le Joncour A, Bidegain F, Ziol M, Galicier L, Oksenhendler E. 56.  et al. 2016. Hemophagocytic lymphohistiocytosis associated with Bartonella henselae infection in an HIV-infected patient. Clin. Infect. Dis. 62:804–6 [Google Scholar]
  57. Untanu RV, Akbar S, Graziano S, Vajpayee N. 57.  2016. Histoplasmosis-induced hemophagocytic lymphohistiocytosis in an adult patient: a case report and review of the literature. Case Rep. Infect. Dis. 2016:1358742 [Google Scholar]
  58. Colomba C, Di Carlo P, Scarlata F, Iaria C, Barberi G. 58.  et al. 2016. Visceral leishmaniasis, hypertriglyceridemia and secondary hemophagocytic lymphohistiocytosis. Infection 44:391–92 [Google Scholar]
  59. Akel T, Mobarakai N. 59.  2017. Hematologic manifestations of babesiosis. Ann. Clin. Microbiol. Antimicrob. 16:6 [Google Scholar]
  60. Sung PS, Kim IH, Lee JH, Park JW. 60.  2011. Hemophagocytic lymphohistiocytosis (HLH) associated with Plasmodium vivax infection: case report and review of the literature. Chonnam Med. J 47173–76 [Google Scholar]
  61. Tseng YT, Sheng WH, Lin BH, Lin CW, Wang JT. 61.  et al. 2011. Causes, clinical symptoms, and outcomes of infectious diseases associated with hemophagocytic lymphohistiocytosis in Taiwanese adults. J. Microbiol. Immunol. Infect. 44:191–97 [Google Scholar]
  62. Brito-Zeron P, Bosch X, Perez-de-Lis M, Perez-Alvarez R, Fraile G. 62.  et al. 2016. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin. Arthritis Rheum. 45:391–99 [Google Scholar]
  63. Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I. 63.  et al. 2015. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br. J. Haematol. 170:539–49 [Google Scholar]
  64. Hadchouel M, Prieur AM, Griscelli C. 64.  1985. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr. 106:561–66 [Google Scholar]
  65. Minoia F, Davi S, Horne A, Demirkaya E, Bovis F. 65.  et al. 2014. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66:3160–69 [Google Scholar]
  66. Nikiforow S, Berliner N. 66.  2015. The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults. Hematol. Am. Soc. Hematol. Educ. Program 2015:183–89 [Google Scholar]
  67. Akima M, Sumi SM. 67.  1984. Neuropathology of familial erythrophagocytic lymphohistiocytosis: six cases and review of the literature. Hum. Pathol. 15:161–68 [Google Scholar]
  68. Haddad E, Sulis ML, Jabado N, Blanche S, Fischer A, Tardieu M. 68.  1997. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 89:794–800 [Google Scholar]
  69. Henter JI, Nennesmo I. 69.  1997. Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J. Pediatr. 130:358–65 [Google Scholar]
  70. Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA. 70.  2002. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch. Dermatol. 138:1208–12 [Google Scholar]
  71. Fardet L, Galicier L, Vignon-Pennamen MD, Regnier S, Noguera ME. 71.  et al. 2010. Frequency, clinical features, and prognosis of cutaneous manifestations in adult patients with reactive haemophagocytic syndrome. Br. J. Dermatol. 162:547–53 [Google Scholar]
  72. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL. 72.  et al. 2010. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116:1574–84 [Google Scholar]
  73. Allen CE, Yu X, Kozinetz CA, McClain KL. 73.  2008. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 50:1227–35 [Google Scholar]
  74. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E. 74.  et al. 2015. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125:1548–52 [Google Scholar]
  75. Chung HJ, Park CJ, Lim JH, Jang S, Chi HS. 75.  et al. 2010. Establishment of a reference interval for natural killer cell activity through flow cytometry and its clinical application in the diagnosis of hemophagocytic lymphohistiocytosis. Int. J. Lab. Hematol. 32:239–47 [Google Scholar]
  76. Li F, Li P, Zhang R, Yang G, Ji D. 76.  et al. 2014. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med. Oncol 31902 [Google Scholar]
  77. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. 77.  2014. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann. Hematol. 93:821–26 [Google Scholar]
  78. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G. 78.  et al. 2006. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107:373–80 [Google Scholar]
  79. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E. 79.  et al. 2005. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur. J. Haematol. 74:6–10 [Google Scholar]
  80. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH. 80.  et al. 2007. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr. Blood Cancer 48:124–31 [Google Scholar]
  81. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T. 81.  et al. 2005. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 146:598–604 [Google Scholar]
  82. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C. 82.  et al. 2014. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66:2613–20 [Google Scholar]
  83. Debaugnies F, Mahadeb B, Ferster A, Meuleman N, Rozen L. 83.  et al. 2016. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am. J. Clin. Pathol. 145:862–70 [Google Scholar]
  84. Batu ED, Erden A, Seyhoglu E, Kilic L, Buyukasik Y. 84.  et al. 2017. Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand. J. Rheumatol. 46:44–48 [Google Scholar]
  85. Janka GE. 85.  1983. Familial hemophagocytic lymphohistiocytosis. Eur. J. Pediatr. 140:221–30 [Google Scholar]
  86. Ambruso DR, Hays T, Zwartjes WJ, Tubergen DG, Favara BE. 86.  1980. Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213. Cancer 45:2516–20 [Google Scholar]
  87. Fischer A, Virelizier JL, Arenzana-Seisdedos F, Perez N, Nezelof C, Griscelli C. 87.  1985. Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation. Pediatrics 76:263–68 [Google Scholar]
  88. Henter JI, Elinder G, Finkel Y, Soder O. 88.  1986. Successful induction with chemotherapy including teniposide in familial erythrophagocytic lymphohistiocytosis. Lancet 2:1402 [Google Scholar]
  89. Fischer A, Cerf-Bensussan N, Blanche S, Le Deist F, Bremard-Oury C. 89.  et al. 1986. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J. Pediatr. 108:267–70 [Google Scholar]
  90. Stephan JL, Donadieu J, Ledeist F, Blanche S, Griscelli C, Fischer A. 90.  1993. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 82:2319–23 [Google Scholar]
  91. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G. 91.  et al. 2002. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100:2367–73 [Google Scholar]
  92. Marsh RA, Vaughn G, Kim MO, Li D, Jodele S. 92.  et al. 2010. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood 116:5824–31 [Google Scholar]
  93. Nikiforow S. 93.  2015. The role of hematopoietic stem cell transplantation in treatment of hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. N. Am. 29:943–59 [Google Scholar]
  94. Wang Y, Huang W, Hu L, Cen X, Li L. 94.  et al. 2015. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood 126:2186–92 [Google Scholar]
  95. Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. 95.  2016. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis. J. Hematol. Oncol. 9:84 [Google Scholar]
  96. Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. 96.  2016. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128:60–71 [Google Scholar]
  97. Jordan M, Prof FL, Allen C, De Benedetti F Grom AA. 97.  et al. 2015. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. Blood 126:LBA–3 [Google Scholar]
  98. Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. 98.  1993. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin. Exp. Rheumatol. 11:451–56 [Google Scholar]
  99. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. 99.  2011. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr. Blood Cancer 56:154–55 [Google Scholar]
  100. Arca M, Fardet L, Galicier L, Riviere S, Marzac C. 100.  et al. 2015. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br. J. Haematol. 168:63–68 [Google Scholar]
  101. Filipovich AH. 101.  2011. The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr. Opin. Allergy Clin. Immunol. 11:512–16 [Google Scholar]
  102. Li J, Wang Q, Zheng W, Ma J, Zhang W. 102.  et al. 2014. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore) 93:100–5 [Google Scholar]
  103. Schram AM, Mullally A, Fogerty AE, Massarotti E, Berliner N. 103.  2014. Hemophagocytic lymphohistiocytosis: the Partners Healthcare experience over the past 8 years. Blood 124:4104 (Abstr.) [Google Scholar]
  104. Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. 104.  2014. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am. J. Clin. Pathol. 141:62–71 [Google Scholar]
  105. Ma AD, Fedoriw YD, Roehrs P. 105.  2012. Hyperferritinemia and hemophagocytic lymphohistiocytosis: single institution experience in adult and pediatric patients. Blood 120:2135 (Abstr.) [Google Scholar]
/content/journals/10.1146/annurev-pathol-020117-043625
Loading
/content/journals/10.1146/annurev-pathol-020117-043625
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error